publication venue for
- Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial (vol 29, pg 880, 2023) 2024
- Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial 2023
- Temporal order of clinical and biomarker changes in familial frontotemporal dementia 2022